White paper


Navigating new U.S. serialization requirements for pharma logistics

Download Now

Enacted in 2013, the Drug Quality and Security Act (DQSA) introduced serialization requirements for drug products to enable effective traceability, with ramifications for pharmaceutical companies’ logistics needs when operating in the U.S.

With the deadline for phase 2 on the rapidly-approaching horizon, fresh challenges emerge for every organization along the pharmaceutical and biotech supply chain — not just manufacturers, but third-party logistics (3PL) providers, wholesalers, and dispensers, too.

How can companies ensure that they have the right supply chain solution to meet future track and trace compliance needs? Access this insightful white paper now to better understand the ‘what’ and ‘why’ of these changes, and ultimately how to ensure total supply chain compliancy.

What can be gained from this white paper

  • An in-depth understanding of the provisions of the new FDA requirements and the reasons for the new legislation.
  • Awareness of the benefits that can be gained from these new requirements not just for pharmaceutical companies’ brand reputation, but ultimately for patient safety.
  • Knowledge of the steps as to how pharmaceutical companies can ensure they remain compliant with changing U.S. requirements.

Download now

Download Now

To download your white paper please enter your details in the form below.

By submitting this form, you understand that ICS may process your data as described in the Cencora privacy statement.

By submitting the form you agree to our Terms and Conditions

Who we are

25+ years of experience. 100% committed to your success.

Since 1997, ICS has partnered with pharmaceutical manufacturers to deliver customized healthcare logistics solutions that improve the quality and efficiency of their supply chains.

Tell me more